Mcl1 Degrader-1

Mcl1 Degrader-1 是一种自噬靶向嵌合体 (AUTAC),可选择性降解 Mcl1 蛋白,其通过 TRAF6/UBC13 介导 Mcl1 发生 K63 泛素化,经 p62/SQSTM1 转运至自噬溶酶体降解,并激活 Beclin1 依赖性自噬 (autophagy),可用于多发性骨髓瘤、非小细胞肺癌的相关研究。
Mcl1 Degrader-1
产品编号: MS-W25152 分子式: C51H54BrFN10O8S 分子量: 1066.00
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Mcl1 Degrader-1 是一种自噬靶向嵌合体 (AUTAC),可选择性降解 Mcl1 蛋白,其通过 TRAF6/UBC13 介导 Mcl1 发生 K63 泛素化,经 p62/SQSTM1 转运至自噬溶酶体降解,并激活 Beclin1 依赖性自噬 (autophagy),可用于多发性骨髓瘤、非小细胞肺癌的相关研究。

生物实验数据

生物活性 Mcl1 Degrader-1 is an autophagy-targeting chimera (AUTAC) that selectively degrades Mcl1 protein by mediating K63 ubiquitination of Mcl1 via TRAF6/UBC13, transporting it through p62/SQSTM1 to autolysosomes for degradation, and activating Beclin1-dependent autophagy, and it can be used for research related to multiple myeloma and non-small cell lung cancer.
IC50 & Target

Mcl-1

 

体外研究
(In Vitro)

Mcl1 Degrader-1 (AUTAC) 相对于 Bcl2 和 Bclxl 选择性结合 Mcl1。
Mcl1 Degrader-1 (100 nM-10 μM; 24-48 h) 可在体外 U266B1 细胞中以剂量和时间依赖的方式选择性降解 Mcl1,但不降解 Bcl2 或 Bclxl,同时还能激活自噬。
Mcl1 Degrader-1 (5 μM; 24 h) 需要自噬才能在 U266B1 细胞中降解 Mcl1。
Mcl1 Degrader-1 (0.1-10 μM; 24-72 h) 可降低 U266B1 和 RPMI-8226 多发性骨髓瘤细胞的活力并诱导细胞死亡,该作用呈时间依赖性;在 U266B1 细胞中作用 48 h 时其 IC50 为 5 μM。
Mcl1 Degrader-1 (10 μM; 24 h) 可在 U266B1 细胞中使 Mcl1 与 Beclin1 解离,并提高 Beclin1 的磷酸化水平,从而激活依赖 Beclin1 的自噬。
Mcl1 Degrader-1 (5-10 μM; 16-24 h) 可在 U266B1 细胞中促进 Mcl1 的 K63 连接泛素化及其与 p62/SQSTM1 的结合,进而与 LC3B 共定位以实现选择性自噬降解。
Mcl1 Degrader-1 (5 μM; 24-72 h) 降解 Mcl1 并诱导 U266B1 细胞发生凋亡性细胞死亡的过程需要 p62/SQSTM1、TRAF6 和 UBC13 的参与;对这些蛋白进行基因敲低后,该化合物的活性会被消除,这一结果证实了上述结论。
Mcl1 Degrader-1 (5 μM; 16-72 h) 联合 Carfilzomib (MS-D41075) 在 U266B1 细胞中增强 Mcl1 降解的过程依赖于 NRF1、功能性自噬 (通过 ATG5) 以及 p62/SQSTM1。
Mcl1 Degrader-1 (500 nM-5 μM; 16-72 h) 在野生型及蛋白酶体抑制剂耐药的多发性骨髓瘤和 NSCLC 细胞中,可通过自噬流的增强来被 Carfilzomib 提升其 Mcl1 降解作用。
Mcl1 Degrader-1 (5 μM; 72 h) 与 Carfilzomib 可协同降低野生型及蛋白酶体抑制剂耐药的多发性骨髓瘤和非小细胞肺癌 (NSCLC) 细胞的活力并诱导其凋亡,且该协同作用依赖于 p62/SQSTM1。

Western Blot Analysis

Cell Line: U266B1 multiple myeloma cells
Concentration: 100 nM, 500 nM, 1 μM, 5 μM, 10 μM (Mcl1 AUTAC);
5 μM (Mcl1 AUTAC, Mcl1-binding moiety); 10 μM (FBnG)
Incubation Time: 24 h, 48 h (Mcl1 AUTAC); 24 h (individual components, starvation)
Result: Reduced Mcl1 protein levels in a dose- and time-dependent manner, with no observable effect on Bcl2 or Bclxl.
Increased LC3 I/II levels, indicating autophagy activation.
Showed no effect on Mcl1 expression when used as individual components; starvation-induced autophagy also did not reduce Mcl1 levels.

Western Blot Analysis

Cell Line: U266B1 multiple myeloma cells, ATG5-knockdown U266B1 multiple myeloma cells
Concentration: 5 μM (Mcl1 AUTAC); 20 μM (CQ); 1 mM (3-MA)
Incubation Time: 24 h
Result: Rescued Mcl1 degradation when combined with CQ or 3-MA.
Led to greater LC3II accumulation when combined with CQ compared to CQ alone.
Alleviated Mcl1 degradation in ATG5-knockdown cells.

Cell Viability Assay

Cell Line: U266B1 and RPMI-8226 multiple myeloma cells
Concentration: 0.1, 0.5, 1, 5, 10 μM (Mcl1 AUTAC); 5 μM (Mcl1 AUTAC, Mcl1-binding moiety, FBnG)
Incubation Time: 24 h, 48 h, 72 h (Mcl1 AUTAC); 24 h (individual components, starvation)
Result: Reduced cell viability in a time-dependent manner, with an IC50 of 5 μM after 48 h in U266B1 cells and 10 μM after 48 h in RPMI-8226 cells.
Induced approximately 50% cell death at 48 h and 60% at 72 h in U266B1 cells.
Caused robust accumulation of cleaved caspase 3 and cleaved PARP at 24 and 48 h.
Showed no caspase 3 cleavage when used as individual components; starvation also did not induce caspase 3 cleavage.

Western Blot Analysis

Cell Line: U266B1 multiple myeloma cells
Concentration: 10 μM
Incubation Time: 24 h
Result: Reduced the binding between Mcl1 and Beclin1.
Increased the phosphorylation of Beclin1.

Immunofluorescence

Cell Line: U266B1 multiple myeloma cells
Concentration: 5, 10 μM
Incubation Time: 16 h, 24 h
Result: Induced clear colocalization of Mcl1 with K63-linked ubiquitin, p62/SQSTM1, and LC3B.
Increased the binding of Mcl1 to both K63-linked ubiquitin and p62/SQSTM1.

Western Blot Analysis

Cell Line: U266B1 multiple myeloma cells, p62/SQSTM1-knockdown U266B1 multiple myeloma cells, TRAF6-knockdown U266B1 multiple myeloma cells, UBC13-knockdown U266B1 multiple myeloma cells
Concentration: 5 μM
Incubation Time: 24 h, 72 h
Result: Abolished Mcl1 degradation and reduced accumulation of cleaved caspase 3 and cleaved PARP in p62/SQSTM1-knockdown cells.
Suppressed Mcl1 degradation and PARP cleavage in TRAF6 or UBC13-knockdown cells.
Reduced U266B1WT cell viability by over 50%, but blunted this cytotoxic response in p62/SQSTM1, TRAF6, or UBC13-knockdown cells.

Western Blot Analysis

Cell Line: multiple myeloma (U266B1, MM.1S, RPMI-8226, AMO-1, U266B1R, AMO-1R) and non-small cell lung cancer (NCI-H1975, NCI-H1975R) cells
Concentration: 500 nM-5 μM (Mcl1 AUTAC); 2.5 nM, 10 nM (carfilzomib)
Incubation Time: 16 h, 24 h, 48 h, 72 h
Result: Enhanced Mcl1 degradation across all tested cell lines, including proteasome inhibitor-resistant lines, when combined with CFZ.
Increased LC3I/II levels, indicating enhanced autophagic flux, when combined with CFZ.
Showed more pronounced reduction in Mcl1 levels, increased accumulation of LC3B and LAMP1, and greater colocalization of Mcl1 with these markers in U266B1 cells when combined with CFZ.

Western Blot Analysis

Cell Line: U266B1 multiple myeloma cells, NRF1-knockout U266B1 multiple myeloma cells, ATG5-knockdown U266B1 multiple myeloma cells, p62/SQSTM1-knockdown U266B1 multiple myeloma cells
Concentration: 5 μM (Mcl1 AUTAC); 10 nM (carfilzomib)
Incubation Time: 16 h, 24 h, 72 h
Result: Lost enhanced Mcl1 degradation by the Mcl1 AUTAC + CFZ combination in NRF1-knockout cells, with diminished LC3I/II levels.
Attenuated Mcl1 degradation by the Mcl1 AUTAC + CFZ combination in ATG5-knockdown cells.
Completely abolished Mcl1 degradation induced by the Mcl1 AUTAC + CFZ combination in p62/SQSTM1-knockdown cells.
Showed standalone Mcl1 degradation, autophagy induction, and cell death that were not dependent on NRF1.
体内研究
(In Vivo)

Mcl1 Degrader-1 (AUTAC) (50 mg/kg;腹腔注射;每日 1 次;第 6 天开始给药直至研究终点),与 Carfilzomib 联用时,相较于溶媒对照组可使 U266B1 多发性骨髓瘤异种移植瘤体积显著降低约 75%,同时伴随 Mcl1 降解及自噬诱导,且未观察到急性毒性。

Animal Model: NOD-SCID-IL2Rγ (NSG) (male and female, 4-6 weeks old, subcutaneous xenograft of U266B1 multiple myeloma cells)
Dosage: 50 mg/kg
Administration: i.p.; once daily; initiated on day 6 until study endpoint
Result: Reduced mean tumor volume to ~300 mm3 compared to ~1200 mm3 for vehicle, ~500 mm3 for carfilzomib alone, and ~800 mm3 for monotherapy.
Reduced Mcl1/GAPDH ratio to ~0.7 vs ~1.0 for vehicle.
Increased LC3II/GAPDH ratio to ~1.4 vs ~1.0 for vehicle.
Showed no significant effect on Bcl2 or Bclxl levels.
Caused no significant changes in mouse body weight.

化学信息

分子量 1066.00
分子式 C51H54BrFN10O8S

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础